Nov 8, 2012 by Brian Orelli, PhDWhat Do Merck Investors Need to Watch?Two things to watch at this pharmaceutical giant.
Nov 8, 2012 by Brian Orelli, PhDThis Biotech Sold Itself ShortSarepta sold shares before strong data shot its share price up.
Nov 7, 2012 by Brian Orelli, PhDA Blockbuster in the MakingPfizer gains FDA approval of its rheumatoid arthritis drug Xeljanz.
Nov 6, 2012 by Brian Orelli, PhDIs Merck's Opportunity Unraveling?What is this pharma giant's market opportunity?
Nov 6, 2012 by Brian Orelli, PhDShocker! No Instant Love for Obesity DrugsThere's still potential though.
Nov 6, 2012 by Brian Orelli, PhDDown 20%: What Is VIVUS' Market Opportunity?Can this pharma company recover from one bad quarter?
Nov 5, 2012 by Brian Orelli, PhDDendreon's Date With DestinyAn upcoming clinical trial could be a major inflection point.
Nov 5, 2012 by Brian Orelli, PhDWhat to Watch With This Obesity Drugmaker's EarningsA few weeks of sales of VIVUS' Qsymia won't really matter.
Nov 2, 2012 by Brian Orelli, PhDFor Hep C Investors, What Goes Around Comes AroundSales of Vertex's Incivek slip as hepatitis C patients wait for better treatments.
Nov 1, 2012 by Brian Orelli, PhDA Hep C Love TriangleVertex pairs up with GlaxoSmithKline and Johnson and Johnson.
Nov 1, 2012 by Brian Orelli, PhDThis Year's Worst Pharma StockBristol's struggling pipeline has the stock price failing to keep up with its peers.
Oct 31, 2012 by Brian Orelli, PhDCoagulating Even More RevenueBiogen presents positive data for a second hemophilia drug.
Oct 31, 2012 by Brian Orelli, PhDBeat and Raise: Big Biotechs' Outstanding QuarterThe four big biotechs exceed both analysts' and their own expectations in the third quarter.
Oct 31, 2012 by Brian Orelli, PhDThe Small Change That's a Big DealGilead tweaks Viread to lower side effects.
Oct 31, 2012 by Brian Orelli, PhD3 Biotechs Investors Should Be Scared OfThey're scary beyond the usual biotech fright.
Oct 29, 2012 by Brian Orelli, PhDIgnore the Noise With This PharmaMerck has both positive and negative one-time issues that investors should ignore.
Oct 26, 2012 by Brian Orelli, PhDThis Biotech Is Looking Good, Ready for MoreBiogen Idec posts solid third-quarter earnings.
Oct 25, 2012 by Brian Orelli, PhDEyeing a Sandbagged GuidanceRegeneron ups guidance for the fourth time this year, but it still might be too low.
Oct 24, 2012 by Brian Orelli, PhDThis Big Biotech Rejoices, but for How Long?Gilead posts solid third quarter results, but its valuation is tied to its pipeline.
Oct 24, 2012 by Brian Orelli, PhDGoing Back for Drug Tech SecondsAbbott expands its deal with Seattle Genetics to include additional drugs.
